Amgen's New Lung Cancer Drug Cuts Death Risk by 40%

Image Credit: Reuters

Amgen’s Imdelltra drug minimizes the risk of death by 40% in comparison to chemotherapy, mainly for small-cell lung cancer patients. The drug will help cure these patients after their worst condition, after the initial round of chemotherapy. The phase 3 trial of 509 patients showed that the Imdelltra drug works as an extended survival for patients. The study revealed that the survival exceeds by more than 5 months to 13.6 months in comparison to 8.3 months of survival duration in standard-of-care chemotherapy.

The Drug

Amgen’s drug is introduced as a treatment named ‘bispecific antibody’. It is developed to merge with the medication for cancer, connecting to the immune cell and the cancer cell. By combining these two cells, the body’s immune system will be able to fight cancer.

Impact

The impact of drugs ensures that the patients live without deteriorating their current disease. A measure called ‘progression-free survival’ consists of 3.7 months for patients who received chemotherapy and 4.2 months for the Imdelltra group. The drug was introduced at the American Society of Clinical Oncology’s annual meeting, which was held in Chicago, and later published in the New England Journal of Medicine. It has been observed that the lung-cancer cases are non-small cell. Whereas, 15% of cases are violent small cell groups on which Imdelltra is focusing.

Views and Statements

Witnessing multiple opinions and reviews on the drug reaction, Amgen said that the results of the trial were initiated to provide confirmatory evidence to contribute to last year’s approval. The approval from the US Food and Drug Administration of Imdelltra for patients was a valuable move. Additionally, 27% of trial patients treated under Imdelltra experienced side effects like low white blood cell count. In comparison, this number is less than 62% of the chemotherapy patients.